Special Feature

The goal of biosimilar manufacturers is to create a drug that features a chemical structure that is extremely close to or the same as the reference or originator drug, demonstrating sufficiently similar morphology and clinical efficacy and safety outcomes that are essentially the same as the reference drug.

In 2014, the introductions of sofosbuvir (Sovaldi) and ledipasvir plus sofosbuvir (Harvoni) for the treatment of hepatitis C raised concerns among the employer community in the United States. The cost implications of these specialty drugs, based on the possibility of their widespread use in patients without advanced disease, had corporate executives hurriedly recalculating their healthcare budgets.

Results 1 - 2 of 2
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME